Procedures for Monitoring Recombinant Erythropoietin and Analogs in Doping

Endocrinology and Metabolism Clinics of North America

Volumn 39, Issue 1, 2010, Pages 141-154

  Lamon, Séverine ^a   Robinson, Neil ^a   Saugy, Martial ^a  

^a University Center of Legal Medicine   (Switzerland)

Author keywords

Anti doping; Athletic performance; Human EPO; Recombinant erythropoietin

Indexed keywords

HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

AEROBIC CAPACITY; ATHLETE; DOPING; DRUG ABUSE; ELECTROSPRAY MASS SPECTROMETRY; ENDURANCE SPORT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; ISOELECTRIC FOCUSING; NONHUMAN; OXYGEN CONSUMPTION; PHYSICAL ACTIVITY; PHYSICAL PERFORMANCE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; REVIEW;

ATHLETIC PERFORMANCE; DOPING IN SPORTS; ERYTHROPOIETIN, RECOMBINANT; FALSE POSITIVE REACTIONS; HEMATOCRIT; HEMOGLOBINS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; IMMUNOASSAY; ISOELECTRIC FOCUSING; OXYGEN CONSUMPTION;

EID: 74049135635     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2009.10.004     Document Type: Review

References (50)

1. Miyake T., Kung C.K., and Goldwasser E. Purification of human erythropoietin. J Biol Chem 252 15 (1977) 5558-5564
2. Lin F.K., Suggs S., Lin C.H., et al. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci U S A 82 22 (1985) 7580-7584
3. Cea B. Erythropoietin: molecular physiology and clinical application (1993), M. Dekker, New York
4. Schonholzer C., Keusch G., Nigg L., et al. High prevalence in Switzerland of pure red-cell aplasia due to anti-erythropoietin antibodies in chronic dialysis patients: report of five cases. Nephrol Dial Transplant 19 8 (2004) 2121-2125
5. Peces R., de la Torre M., Alcazar R., et al. Antibodies against recombinant human erythropoietin in a patient with erythropoietin-resistant anemia. N Engl J Med 335 7 (1996) 523-524
6. Davis J.M., Arakawa T., Strickland T.W., et al. Characterization of recombinant human erythropoietin produced in Chinese hamster ovary cells. Biochemistry 26 9 (1987) 2633-2638
7. Jelkmann W. The enigma of the metabolic fate of circulating erythropoietin (Epo) in view of the pharmacokinetics of the recombinant drugs rhEpo and NESP. Eur J Haematol 69 5-6 (2002) 265-274
8. Barbone F.P., Johnson D.L., Farrell F.X., et al. New epoetin molecules and novel therapeutic approaches. Nephrol Dial Transplant 14 Suppl 2 (1999) 80-84
9. Schellekens H. The first biosimilar epoetin: but how similar is it?. Clin J Am Soc Nephrol 3 1 (2008) 174-178
10. Macdougall I.C., and Ashenden M. Current and upcoming erythropoiesis-stimulating agents, iron products, and other novel anemia medications. Adv Chronic Kidney Dis 16 2 (2009) 117-130
11. Adamson J.W., and Vapnek D. Recombinant erythropoietin to improve athletic performance. N Engl J Med 324 10 (1991) 698-699
12. Bulbulian R., Wilcox A.R., and Darabos B.L. Anaerobic contribution to distance running performance of trained cross-country athletes. Med Sci Sports Exerc 18 1 (1986) 107-113
13. Craig N.P., Norton K.I., Bourdon P.C., et al. Aerobic and anaerobic indices contributing to track endurance cycling performance. Eur J Appl Physiol Occup Physiol 67 2 (1993) 150-158
14. Wagner P.D. New ideas on limitations to VO2max. Exerc Sport Sci Rev 28 1 (2000) 10-14
15. Berglund B., and Ekblom B. Effect of recombinant human erythropoietin treatment on blood pressure and some haematological parameters in healthy men. J Intern Med 229 2 (1991) 125-130
16. Audran M., Gareau R., Matecki S., et al. Effects of erythropoietin administration in training athletes and possible indirect detection in doping control. Med Sci Sports Exerc 31 5 (1999) 639-645
17. Ekblom B., and Berglund B. Effect of erythropoietin administration on mammal aerobic power. Scand J Med Sci Sports 1 2 (1991) 88-92
18. Casoni I., Ricci G., Ballarin E., et al. Hematological indices of erythropoietin administration in athletes. Int J Sports Med 14 6 (1993) 307-311
19. Gareau R., Audran M., Baynes R.D., et al. Erythropoietin abuse in athletes. Nature 380 6570 (1996) 113
20. Robinson N., Mangin P., Schattenberg L., et al. Origine du suivi hématologique: les contrôles hématocrites dans le cyclisme. (février 2003). Revue Française des Laboratoires 350 (2003) 53-59 [in French]
21. Parisotto R., Gore C.J., Emslie K.R., et al. A novel method utilising markers of altered erythropoiesis for the detection of recombinant human erythropoietin abuse in athletes. Haematologica 85 6 (2000) 564-572
22. Parisotto R., Wu M., Ashenden M.J., et al. Detection of recombinant human erythropoietin abuse in athletes utilizing markers of altered erythropoiesis. Haematologica 86 2 (2001) 128-137
23. Lasne F., and de Ceaurriz J. Recombinant erythropoietin in urine. Nature 405 6787 (2000) 635
24. Wang M.D., Yang M., Huzel N., et al. Erythropoietin production from CHO cells grown by continuous culture in a fluidized-bed bioreactor. Biotechnol Bioeng 77 2 (2002) 194-203
25. Choi D., Kim M., and Park J. Erythropoietin: physico- and biochemical analysis. J Chromatogr B Biomed Appl 687 1 (1996) 189-199
26. Wide L., Bengtsson C., Berglund B., et al. Detection in blood and urine of recombinant erythropoietin administered to healthy men. Med Sci Sports Exerc 27 11 (1995) 1569-1576
27. Lasne F. Double-blotting: a solution to the problem of nonspecific binding of secondary antibodies in immunoblotting procedures. J Immunol Methods 276 1-2 (2003) 223-226
28. Lasne F., Martin L., Crepin N., et al. Detection of isoelectric profiles of erythropoietin in urine: differentiation of natural and administered recombinant hormones. Anal Biochem 311 2 (2002) 119-126
29. Wide L., and Bengtsson C. Molecular charge heterogeneity of human serum erythropoietin. Br J Haematol 76 1 (1990) 121-127
30. Catlin D.H., Breidbach A., Elliott S., et al. Comparison of the isoelectric focusing patterns of darbepoetin alfa, recombinant human erythropoietin, and endogenous erythropoietin from human urine. Clin Chem 48 11 (2002) 2057-2059
31. Breidbach A., Catlin D.H., Green G.A., et al. Detection of recombinant human erythropoietin in urine by isoelectric focusing. Clin Chem 49 6 Pt 1 (2003) 901-907
32. Wide L., Wikstrom B., and Eriksson K. A new principle suggested for detection of darbepoetin-alpha (NESP) doping. Ups J Med Sci 108 3 (2003) 229-238
33. Lasne F., Martin L., Martin J.A., et al. Isoelectric profiles of human erythropoietin are different in serum and urine. Int J Biol Macromol 41 3 (2007) 354-357
34. Lönnberg M., Drevin M., and Carlsson J. Ultra-sensitive immunochromatographic assay for quantitative determination of erythropoietin. J Immunol Methods 339 2 (2008) 236-244
35. Franke W.W., and Heid H. Pitfalls, errors and risks of false-positive results in urinary EPO drug tests. Clin Chim Acta 373 1-2 (2006) 189-190
36. Beullens M., Delanghe J.R., and Bollen M. False-positive detection of recombinant human erythropoietin in urine following strenuous physical exercise. Blood 107 12 (2006) 4711-4713
37. Kahn A., and Baker M. Non-specific binding of monoclonal human erythropoietin antibody AE7A5 to Escherichia coli and Saccharomyces cerevisiae proteins. Clin Chim Acta 379 (2006) 173-175
38. Khan A., Grinyer J., Truong S.T., et al. New urinary EPO drug testing method using two-dimensional gel electrophoresis. Clin Chim Acta 358 1-2 (2005) 119-130
39. Rabin O.P., Lasne F., Pascual J.A., et al. New urinary EPO drug testing method using two-dimensional gel electrophoresis. Clin Chim Acta 373 1-2 (2006) 186-187
40. Reichel C. Identification of zinc-alpha-2-glycoprotein binding to clone AE7A5 antihuman EPO antibody by means of nano-HPLC and high-resolution high-mass accuracy ESI-MS/MS. J Mass Spectrom 43 7 (2008) 916-923
41. Lamon S., Martin L., Robinson N., et al. Effects of exercise on the isoelectric patterns of erythropoietin. Clin J Sport Med 19 (2009) 311-315
42. WADA. Technical document TD2009 EPO. Available at: http://www.wada-ama.org. Accessed 2009.
43. Ashenden M., Varlet-Marie E., Lasne F., et al. The effects of microdose recombinant human erythropoietin regimens in athletes. Haematologica 91 8 (2006) 1143-1144
44. Caldini A., Moneti G., Fanelli A., et al. Epoetin alpha, epoetin beta and darbepoetin alfa: two-dimensional gel electrophoresis isoforms characterization and mass spectrometry analysis. Proteomics 3 6 (2003) 937-941
45. Reichel C., Kulovics R., Jordan V., et al. SDS-PAGE of recombinant and endogenous erythropoietins: benefits and limitations of the method for application in doping control. Drug Test Anal 1 (2009) 43-50
46. Lonnberg M., and Carlsson J. Lab-on-a-chip technology for determination of protein isoform profiles. J Chromatogr A 1127 1-2 (2006) 175-182
47. Stubiger G., Marchetti M., Nagano M., et al. Characterisation of intact recombinant human erythropoietins applied in doping by means of planar gel electrophoretic techniques and matrix-assisted laser desorption/ionisation linear time-of-flight mass spectrometry. Rapid Commun Mass Spectrom 19 5 (2005) 728-742
48. Guan F., Uboh C.E., Soma L.R., et al. Differentiation and identification of recombinant human erythropoietin and darbepoetin Alfa in equine plasma by LC-MS/MS for doping control. Anal Chem 80 10 (2008) 3811-3817
49. Guan F., Uboh C.E., Soma L.R., et al. Identification of darbepoetin alfa in human plasma by liquid chromatography coupled to mass spectrometry for doping control. Int J Sports Med 30 2 (2009) 80-86
50. Groleau P.E., Desharnais P., Cote L., et al. Low LC-MS/MS detection of glycopeptides released from pmol levels of recombinant erythropoietin using nanoflow HPLC-chip electrospray ionization. J Mass Spectrom 43 7 (2008) 924-935